Elie Dheilly

Title: Elie Dheilly: Innovator in Bispecific Antibodies

Introduction

Elie Dheilly is a prominent inventor based in La Chaux-de-Fonds, Switzerland. He has made significant contributions to the field of immunology, particularly through his innovative work on bispecific antibodies. His research focuses on developing novel therapeutic solutions for autoimmune and proliferative diseases, including various forms of cancer.

Latest Patents

Elie Dheilly holds 1 patent for his invention titled "CD47-CD38 bispecific antibodies." This patent describes a new class of bispecific heterodimeric immunoglobulins that target both the human CD47 antigen and the human CD38 antigen. The invention includes antibodies that comprise an anti-CD38 heavy chain variable region and a light chain variable region, as well as an anti-CD47 heavy chain variable region and a light chain variable region. The application of these bispecific antibodies is particularly relevant for treating hematologic malignancies and solid tumors.

Career Highlights

Elie Dheilly is associated with Igi Therapeutics SA, where he continues to advance his research in the field of immunotherapy. His work is pivotal in the development of new treatment options that could significantly improve patient outcomes in oncology.

Collaborations

Elie Dheilly collaborates with talented professionals in his field, including Laure Bouchez and Blandine Pouleau. Their combined expertise contributes to the innovative research and development efforts at Igi Therapeutics SA.

Conclusion

Elie Dheilly's contributions to the field of bispecific antibodies represent a significant advancement in the treatment of complex diseases. His innovative approach and dedication to research continue to pave the way for new therapeutic strategies in immunology.